ProfileGDS5678 / 1456380_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 96% 95% 96% 96% 96% 94% 94% 95% 96% 97% 97% 96% 97% 97% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 19.0287596
GSM967853U87-EV human glioblastoma xenograft - Control 28.5191995
GSM967854U87-EV human glioblastoma xenograft - Control 38.9319996
GSM967855U87-EV human glioblastoma xenograft - Control 48.8614896
GSM967856U87-EV human glioblastoma xenograft - Control 59.1073296
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.8448994
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.8813294
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.434495
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 48.772696
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 19.1743797
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 29.1323697
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 39.0561796
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 49.4762497
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 59.1387897